Abstract: Novel short peptides of up to about 20 amino acid residues are disclosed that bind to the SEC receptor. These novel peptides preferably are pentapeptides which are synthetic analogs of a pentapeptide domain in the carboxy-terminal fragment of .alpha..sub.1 -antitrypsin (amino acids 370-374, Phe-Val-Phe-Leu-Met [SEQ ID NO:2]). A preferred binding peptide is Phe-Val-Ala-Leu-Met [SEQ ID NO;6].
Type:
Grant
Filed:
April 24, 1991
Date of Patent:
December 29, 1992
Assignee:
Washington University
Inventors:
Robert J. Fallon, Joseph W. Bulock, Steven P. Adams, David H. Perlmutter
Abstract: Method of manufacturing an intravenously tolerable immunoglobulin-G preparation that is free of aggregates, vasoactive substances and proteolytic enzymes and accordingly appropriate for all types of patients, especially immunosuppressed patients, from a starting material that contains immunoglobulin G but from which the coagulation factors have been removed. The starting material is treated with 0.4 to 1.5% by volume of octanoic acid and then chromatographed, especially on an ion or cation exchanger or hydrophobic matrix.
Abstract: There is provided a novel therapeutic agent for use in the prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy, as well as a method of prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy with the therapeutic agent, and a method of prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy with the therapeutic agent in combination with one or more other agents indicated for the treatment of acute nonlymphocytic leukemia.
Abstract: Methods of enhancing immunoglobulin fragment yield of immunoglobulins exhibiting anomalous bands when analyzed by SDS-PAGE techniques are provided. Such yield enhancement methods include the steps of desialylating the immunoglobulin; and fragmenting the immunoglobulin produced in the desialylating step. A particular advantage of the present invention is that the fragmention step can be carried out in the presence of cysteine without decreasing the quality of the immunoglobulin fragment product. Methods of enhancing the molecular weight homogeneity of immunoglobulin or fragmented immunoglobulin exhibiting anomalous bands when analyzed by SDS-PAGE techniques are also discussed. These methods include the steps of desialylating the immunoglobulin or fragmented immunoglobulin and purifying the desialylated product.
Abstract: Novel bioactive compounds have been isolated from blue-green alga. These compounds have been found to have antitumor, antiviral, and immunomodulatory properties. Thus, these compounds, and derivatives thereof, can be used to treat human and animal tumors, inhibit viral growth, and provide immunomodulatory activity.
Type:
Grant
Filed:
August 8, 1990
Date of Patent:
February 25, 1992
Assignee:
Harbor Branch Oceanographic Institution, Inc.
Inventors:
Frank Koehn, Sue S. Cross, Ross E. Longley